Expression data from canine osteosarcoma primary tumors (Affymetrix Canine 2.0 array)
Ontology highlight
ABSTRACT:
ORGANISM(S): Canis lupus familiaris
PROVIDER: GSE24251 | GEO | 2010/09/22
SECONDARY ACCESSION(S): PRJNA133055
REPOSITORIES: GEO
Similar Datasets
Project description:Some dogs respond well to amputation and chemotherapy and are disease free longer than the median 200 days whereas others experience rapid lung metastasis. Microarrays were used to compare primary tumors of dogs with a disease free interval (DFI) >300 days (n=7) to those with a DFI<100 days (n=8). Chemotherapy naïve primary tumors were collected at the time of amputation and archived at the Animal Cancer Center. Arrays were performed on a total of 15 dogs.
2010-09-22 | E-GEOD-24251 | biostudies-arrayexpress
Project description:Dogs develop osteosarcoma (OSA) and the disease process closely resembles that of human OSA. OSA has a poor prognosis in both species and disease free intervals and cure rates have not improved in recent years. Gene expression in canine OSAs was compared with non-tumor tissue utilising next generation RNA sequencing. The data provides novel insights into the molecular mechanisms of OSA in high risk breeds. This knowledge may inform development of prevention and treatment for OSA in dogs and supports the dog as a model of OSA in people.
2020-10-22 | GSE155646 | GEO
Project description:The recently developed COXEN method (PMID: 17666531) has been used to successfully extrapolate gene signatures of drug sensitivity across different tumor histotypes. We wanted to explore the utility of COXEN to predict chemosensitivity in canine cancer, specifically if we could extrapolate gene signatures identified in human datasets over to canine osteosarcoma tumors. This dataset of canine osteosarcoma tumor samples has available clinical outcome data after patients had infected limbs amputated and were treated with doxorubicin and/or carboplatin. We performed microarray analysis on this panel of tumor samples for validating our COXEN prediction models for doxorubicin or carboplatin sensitivity. Chemotherapy naive primary tumors were collected at the time of amputation and archived at the Flint Animal Cancer Center. RNA was extracted from 33 frozen archived tumor samples, followed by microarray analysis. The gene expression data was RMA preprocessed, scaled and were used as a independent test set to evaluate developed prediction models of sensitivity to doxorubicin or carboplatin. Drug predictions were than compared to clinical outcome in these patients that received doxorubicin and/or carboplatin.
2015-12-18 | E-GEOD-76127 | biostudies-arrayexpress
Project description:Osteosarcoma is the most common primary bone tumours of dogs. Canine osteosarcoma contains a sub-population of cancer stem cells. Here we used canine-specific microarrays to compare the global gene expression profiles of osteosarcoma stem cells to adherent cancer cells and canine mesenchymal stem cells.
2013-11-05 | GSE52063 | GEO
Project description:The recently developed COXEN method (PMID: 17666531) has been used to successfully extrapolate gene signatures of drug sensitivity across different tumor histotypes. We wanted to explore the utility of COXEN to predict chemosensitivity in canine cancer, specifically if we could extrapolate gene signatures identified in human datasets over to canine osteosarcoma tumors. This dataset of canine osteosarcoma tumor samples has available clinical outcome data after patients had infected limbs amputated and were treated with doxorubicin and/or carboplatin. We performed microarray analysis on this panel of tumor samples for validating our COXEN prediction models for doxorubicin or carboplatin sensitivity.
2015-12-18 | GSE76127 | GEO
Project description:Osteosarcoma is the most common primary bone tumours of dogs. Canine osteosarcoma contains a sub-population of cancer stem cells. Here we used canine-specific microarrays to compare the global gene expression profiles of osteosarcoma stem cells to adherent cancer cells and canine mesenchymal stem cells. Canine osteosarcoma spheres were isolated by their ability to form tumourspheres. Spheres, adherent cells and mesenchymal stem cells were harvested and used for RNA extraction and hybridisation on Affymetrix microarrays (Canine 2.0). Four biological replicates of each sample were included.
2013-11-05 | E-GEOD-52063 | biostudies-arrayexpress
Project description:Pulmonary metastasis continues to be the most common cause of death in osteosarcoma. Indeed, the 5-year survival for newly diagnosed osteosarcoma patients has not significantly changed in over 20 years. Further understanding of the mechanisms of metastasis and resistance for this aggressive pediatric cancer is necessary. Pet dogs naturally develop osteosarcoma providing a novel opportunity to model metastasis development and progression. Given the accelerated biology of canine osteosarcoma, we hypothesized that a direct comparison of canine and pediatric osteosarcoma expression profiles may help identify novel metastasis-associated tumor targets that have been missed through the study of the human cancer alone. Collectively, these data support the strong similarities between human and canine osteosarcoma and underline the opportunities provided by a comparative oncology approach as a means to improve our understanding of cancer biology and therapy.
2009-11-04 | GSE16087 | GEO
Project description:Canine pyometra is a common inflammatory disease of the uterus in sexually mature bitches, caused by a secondary bacterial infection which leads to change in the plasma protein associated with the innate immune system. Proteomic offers a means to determine the profile of plasma in dogs with pyometra to provide important findings into general mechanisms operating during diverse inflammatory reactions. The plasma protein profile of healthy and pyometra affected bitches was determined by means of an isobaric tandem mass tag (TMT) label-based high-resolution quantitative proteomic approach. Six clinically healthy dogs (used as control group) and 6 dogs with pyometra were enrolled in the study. All dogs were admitted to the Small Animal Clinic, University of Veterinary Medicine Hannover and treated in accordance with the German Animal Welfare Law. The experimental design was approved by the Animal Welfare officer of the University of Veterinary Medicine and by the Ethic Committee of the responsible authority (Lower Saxony State Office for Consumer Protection and Food Safety, reference number 17A 101). Healthy dogs for blood collection were recruited by launching a call in the University of Veterinary Medicine Hannover network for students and staff members for haemostasis study, providing a free clinical and laboratory health check of their animal in combination with the blood collection. Residual sample material was used in the present study.
2020-05-18 | PXD015951 | Pride
Project description:Pulmonary metastasis continues to be the most common cause of death in osteosarcoma. Indeed, the 5-year survival for newly diagnosed osteosarcoma patients has not significantly changed in over 20 years. Further understanding of the mechanisms of metastasis and resistance for this aggressive pediatric cancer is necessary. Pet dogs naturally develop osteosarcoma providing a novel opportunity to model metastasis development and progression. Given the accelerated biology of canine osteosarcoma, we hypothesized that a direct comparison of canine and pediatric osteosarcoma expression profiles may help identify novel metastasis-associated tumor targets that have been missed through the study of the human cancer alone. Collectively, these data support the strong similarities between human and canine osteosarcoma and underline the opportunities provided by a comparative oncology approach as a means to improve our understanding of cancer biology and therapy. Profiles of dog osteosarcoma and several normal tissues, single channel design, tumor versus normal
2010-05-08 | E-GEOD-16087 | biostudies-arrayexpress
Project description:VSV-IFNβ-NIS is a recombinant oncolytic vesicular stomatitis virus (VSV) that is being evaluated clinically for the treatment of advanced malignancies. As with other cancer immunotherapies, identifying biomarkers of response will be critical to the clinical advancement of this treatment approach. . RNAseq analysis showed that virtually all the long-term responders had increased expression of a CD8 T-cell anchored immune gene cluster. We conclude that neoadjuvant VSV-IFNβ-NIS has an excellent safety profile and may provide a survival benefit for dogs with osteosarcoma whose tumors are permissive for immune infiltration.
2023-10-01 | GSE240033 | GEO